Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

Development and Testing of an Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening - A Pilot Study

The purpose of this study is to test an innovative MRI breast cancer screening method in women with mammographically dense breasts as well as other women with moderately increased cancer risk. MRI, combined with other methods of risk assessment, has potential to significantly improve sensitivity to cancer in dense breasts and detect cancer in all cases at a much earlier stage, with far fewer interval cancers than mammography. Previous tests of MRI sensitivity show that this screening could significantly increase the likelihood of detecting invasive cancers resulting in decreased mortality from breast cancer.

Suspicious lesions will be defined by the clinical interpretation of the breast MRI images performed by the attending breast radiologists. Based on the radiologist determination that the MRI findings are suspicious (these findings include masses, non-mass enhancement and foci), suspicious lesions will be assigned a Bi-Rads code specifying whether additional work up or biopsy is necessary. These are Bi-Rads codes 0, 4 and 5. False positive diagnosis should be minimized as all attending physicians reading breast MRI at this institution are fellowship trained in breast imaging.

Study Overview

• Status: Terminated
• Conditions: Breast Cancer
• Intervention / Treatment: Diagnostic test: MRI Abbreviated Scan; Diagnostic test: Abbreviated MRI Scan

Detailed Description

1. BACKGROUND X-ray mammography has significantly reduced breast cancer mortality, yet many cancers are still detected at advanced stages. Early detection remains the best approach for improving outcomes. MRI offers high sensitivity and can detect cancers-especially aggressive subtypes and those in dense breasts-years earlier than mammography. In areas like south Chicago, with disproportionately high rates of aggressive breast cancer, MRI screening could dramatically reduce morbidity and mortality if implemented effectively.

   Mammography is less effective for women with dense breasts and does not always detect cancer until tumors are relatively large. Women with dense breasts or those at increased risk for aggressive cancers (e.g., triple-negative) often lack adequate screening options. MRI has consistently shown superior sensitivity, and its performance is not diminished by breast density. Concerns remain, however, about MRI's specificity, potential false positives, and perceived cost for general screening. Nevertheless, newer techniques and protocols may mitigate these limitations.

   Routine mammography improves survival by detecting cancers early, but sensitivity can be reduced by 30-50% in dense breasts. Since these women are also at higher risk for aggressive cancers, better screening tools are needed. Earlier detection with MRI could significantly decrease both morbidity and mortality.

   ________________________________________

2. PURPOSE / HYPOTHESIS We propose a novel MRI-based breast cancer screening protocol for women with dense breasts and/or moderately increased risk. Our goal is to establish a fast, quantitative, and cost-effective MRI exam that enhances sensitivity while maintaining acceptable specificity and feasibility for clinical use.

Prior data suggest MRI screening may improve early detection of invasive cancers and reduce interval cancers [1,8,9]. The University of Chicago is uniquely positioned to lead this effort, particularly in underserved areas with high breast cancer burden.

Specific Aims:

1. Develop an abbreviated (<15-minute) quantitative MRI screening protocol and evaluate reproducibility in 10 volunteers with dense breasts.
2. Scan ~50 women with mammographic or sonographic findings requiring biopsy using the short MRI protocol to define thresholds that differentiate benign from malignant lesions.
3. Recruit 150 women with dense breasts and/or intermediate breast cancer risk for short MRI screening.
4. Conduct a reader study using data from women with biopsy-confirmed benign/malignant lesions to evaluate false positive rates.

5. Analyze quantitative metrics from both standard and ultrafast DCE-MRI, including:

   • Ktrans (contrast uptake rate)
   • Initial enhancement time in parenchyma and lesions
   • Novel approaches to Ktrans and arterial input function
   • Vessel count/size and enhancement rate near suspicious lesions These markers, measurable only via ultrafast sequences, will be assessed for false positive rates using thresholds established in Aim 2.

6. Lesions deemed suspicious (BI-RADS 0, 4, 5) by attending breast radiologists will be documented. All readers are fellowship-trained to minimize false positives.

   ________________________________________

3. ELIGIBILITY

Inclusion Criteria:

• Women with mammographic/sonographic findings requiring image-guided biopsy
• OR
• Women aged 30-70 with >10% lifetime risk or dense breasts without current cancer diagnosis The two groups (screening vs. diagnostic) will be matched for parity, menopausal status, and age.

Exclusion Criteria:

• History of contrast media reaction
• Pregnant women
• Those at risk for nephrogenic systemic fibrosis (NSF) ________________________________________ 4. STUDY DESIGN

Enrollment:

• Recruit ~50 women with suspicious findings on mammography (expected: 30 malignant, 20 benign based on biopsy).
• Continue enrollment until 30 cancers are confirmed.
• Additionally, recruit 150 women with dense breasts or intermediate risk.

MRI Protocol:

• <15-minute scan including calibration, bilateral T2, and DCE-MRI sequences.

Ground Truth:

• For diagnostic group: Biopsy results (surgical pathology) will serve as gold standard.

• For screening group:

  1. No suspicious MRI findings = no cancer
  2. Suspicious lesions biopsied = pathology determines status

  3. Suspicious but unbiopsied lesions = considered benign unless progression occurs at 6-month follow-up

     • READER STUDY Radiologists will independently review T2 and post-contrast T1 images, as well as ultrafast sequences, assigning malignancy probability (scale 1-10). ROC curves will assess inter-reader variability and compare reader performance to quantitative metrics. This exploratory aim is not powered for definitive conclusions but will guide future studies.

       ________________________________________

     • STATISTICAL POWER With 30 confirmed cancers and 170 controls (including benign biopsy cases), we will evaluate diagnostic accuracy of several parameters (e.g., Ktrans, initial enhancement time, vascular metrics). ROC analysis will determine optimal thresholds-defined by maximum sensitivity + specificity with specificity >80%. We aim to detect an AUC ≥74% for Ktrans and initial enhancement time at 5% significance.

These thresholds will inform a larger R01-funded validation study, which will include covariate-adjusted ROC analysis across risk strata (e.g., Gail model, family history).

Preliminary ROC curves from the reader study will assess whether visual interpretation of abbreviated MRI aligns with quantitative results, although this aim remains exploratory and not statistically powered.

• Study Type: Observational
• Enrollment (Actual): 166

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago Mitchell Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 74 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Women who have had a mammographically and/or sonographically identified finding that will require image guided biopsy.

Women between ages 40-74 with dense breasts having a mammogram

Women who have been identified as having an average or intermediate risk of breast cancer (defined as 10-20% lifetime risk based on a clinical risk model)

Description

Inclusion Criteria:

• Women that have had a mammographically and/or sonographically identified finding that will require image guided biopsy
• Women between ages 40-74 with dense breasts having a mammogram
• Women identified as having an average or intermediate risk of breast cancer (defined as 10- 20% lifetime risk based on a clinical risk model).

Exclusion Criteria:

• Women with metallic implants
• Women that are claustrophobic
• Women that have a fear of needles or contrast
• Women that have had an allergic reaction to contrast in the past
• Women that are pregnant
• Women who are demonstrated to be at risk for an allergic reaction or nephrogenic systemic fibrosis (NSF)

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Biopsy Group; We will scan 50 women who are scheduled for a breast biopsy. Subjects will receive an MRI exam that is research-only prior to the biopsy.	Diagnostic test: MRI Abbreviated Scan; All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better. The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible.
MRI Unknown Cancer Status Group; We will scan 150 women with dense breasts and/or women who have intermediate risk of breast cancer for this study. Subjects will receive an MRI exam that is research-only.	Diagnostic test: Abbreviated MRI Scan; All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better. The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
True Positive	The number of abbreviated scans that successfully determines a cancer, confirmed by biopsy, based on the radiologist determination that the MRI findings are suspicious. Suspicious lesions were assigned a Bi-Rads code specifying whether additional work up or biopsy is necessary. These are Bi-Rads codes 0 (incomplete - need additional imaging evaluation), 4 (suspicious for malignancy - biopsy should be considered) and 5 (highly suggestive of malignancy - appropriate action should be taken).	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
True Negative	The abbreviated scan successfully determines no cancers are present, as confirmed with mammography or a standard MRI.	30 days

Collaborators and Investigators

• Sponsor: University of Chicago
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Gregory Karczmar, PhD, University of Chicago

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2017
• Primary Completion (Actual): May 31, 2022
• Study Completion (Actual): May 31, 2022

Study Registration Dates

• First Submitted: April 28, 2021
• First Submitted That Met QC Criteria: May 4, 2021
• First Posted (Actual): May 7, 2021

Study Record Updates

• Last Update Posted (Actual): March 20, 2026
• Last Update Submitted That Met QC Criteria: March 19, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Breast cancer; MRI Screening
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms
• Other Study ID Numbers: IRB16-0396; 5R01CA276652-02 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes